PALB2 and lung carcinoma: Previous studies revealed that the prevalence of ATM, CHEK2, PALB2, and TP53 germline P/LP variants ranged from 0.11% to 0.29%, 0.39% to 0.40%, 0.11% to 0.29%, and 0.10% to 0.34%, respectively, in two independent Chinese cohorts of lung cancer patients.13, 14